Skip to main content

Evidence of comparative efficacy should have a formal role in European drug approvals

Publication ,  Journal Article
Sorenson, C; Naci, H; Cylus, J; Mossialos, E
Published in: BMJ
September 6, 2011

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ

DOI

EISSN

1468-5833

ISSN

0959-8138

Publication Date

September 6, 2011

Volume

343

Issue

sep06 1

Start / End Page

d4849 / d4849

Publisher

BMJ

Related Subject Headings

  • General & Internal Medicine
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sorenson, C., Naci, H., Cylus, J., & Mossialos, E. (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ, 343(sep06 1), d4849–d4849. https://doi.org/10.1136/bmj.d4849
Sorenson, C., H. Naci, J. Cylus, and E. Mossialos. “Evidence of comparative efficacy should have a formal role in European drug approvals.” BMJ 343, no. sep06 1 (September 6, 2011): d4849–d4849. https://doi.org/10.1136/bmj.d4849.
Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011 Sep 6;343(sep06 1):d4849–d4849.
Sorenson, C., et al. “Evidence of comparative efficacy should have a formal role in European drug approvals.” BMJ, vol. 343, no. sep06 1, BMJ, Sept. 2011, pp. d4849–d4849. Crossref, doi:10.1136/bmj.d4849.
Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. BMJ; 2011 Sep 6;343(sep06 1):d4849–d4849.

Published In

BMJ

DOI

EISSN

1468-5833

ISSN

0959-8138

Publication Date

September 6, 2011

Volume

343

Issue

sep06 1

Start / End Page

d4849 / d4849

Publisher

BMJ

Related Subject Headings

  • General & Internal Medicine
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences